Clinical Trials Directory

Trials / Completed

CompletedNCT04367545

Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
130 (actual)
Sponsor
University Hospital, Rouen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The objective of the study is to develop and validate a molecular diagnostic strategy (RT-ddPCR multiplex) of COVID-19 based on a saliva sample and alternative to the RT-qPCR method, in order to : 1. to compensate for the risk of a shortage of diagnostic kits, reagents and materials necessary for molecular diagnosis; 2. to increase the molecular diagnostic capacity of COVID-19 at the Rouen University Hospital; 3. and to have a method compatible with screening extended to populations at risk.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTSaliva collectionSaliva collection will be done in addition to standard diagnosis collection (nasopharyngeal collection using swab)

Timeline

Start date
2020-04-16
Primary completion
2020-05-17
Completion
2020-05-17
First posted
2020-04-29
Last updated
2026-04-17

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04367545. Inclusion in this directory is not an endorsement.

Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic (NCT04367545) · Clinical Trials Directory